Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)

European Journal of Clinical Investigation

Volumn 24, Issue 7, 1994, Pages 444-453

  CREMER, P ^a,c   NAGEL, D ^a,c   LABROT, B ^a,c   MANN, H ^a,c   MUCHE, R ^b   ELSTER, H ^a,c   SEIDEL, D ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Volkswagen Ag ^*

^c VOLKSWAGEN AG   (Germany)

Author keywords

Fibrinogen; LDL cholesterol; lipoprotein(a); myocardial infarction

Indexed keywords

CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

COHORT STUDIES; COMPARATIVE STUDY; FIBRINOGEN; HUMAN; INCIDENCE; LIPOPROTEIN(A); LIPOPROTEINS, LDL CHOLESTEROL; MALE; MIDDLE AGE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0028168238     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1994.tb02373.x     Document Type: Article

References (39)

1. Isolation of apolipoprotein(a) from lipoprotein(a)
2. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations
3. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
4. A potential basis for the thrombotic risks associated with lipoprotein(a)
5. Lipoprotein(a): The link between impaired Fibrinolysis and Atherosclerosis
6. Lipoprotein(a). Heterogeneity and biological relevance
7. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions
8. Atherosclerosis and the coagulation system
9. Plasma fibrinogen—an independent cardiovascular risk factor
10. Haemostatic function and ischemic heart disease: principle results of the Northwick Park Heart Study
11. Fibrinogen as a risk factor for stroke and myocardial infarction
12. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham study
13. Lipoprotein Lp(a) and the risk for myocardial infarction
14. Lp(a) lipoprotein as a risk factor for myocardial infarction
15. Lipoprotein(a) as a strong indicator for cerebrovascular disease
16. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis
17. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
18. Lipoprotein(a) and coronary heart disease risk: a nested case‐control study of the Helsinki Heart Study participants
19. Lipoprotein(a) and coronary heart disease: a prospective case‐control study in a general population sample of middle aged men
20. Guidelines for the clinical evaluation of lipoprotein profiles. A first report from the Göttingen Risk Incidence and Prevalence study
21. The electrocardiogram in population studies—a classification system
22. The Lipid Research Clinics coronary primary prevention trial results
23. The World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular disease: a major international collaboration)
24. Incidence rates of fatal and non‐fatal myocardial infarction in relation to the lipoprotein profile: first prospective results from the Göttingen Risk, Incidence, and Prevalence Study (GRIPS)
25. Quantitative lipoprotein electrophoresis
26. Evaluation of a commercial kit for the determination of LDL cholesterol in serum based on precipitation of LDL with dextran sulfate
27. Report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults
28. Significance of risk factors in the prediction of atherosclerosis
29. Epidemiology as a guide to clinical decisions. The Association between triglyceride and coronary heart disease
30. Overall and coronary heart disease mortality rates in relation to major risk factors in 325, 348 men screened for the MRFIT
31. Optimal resources for primary prevention of atherosclerotic diseases
32. Lipoprotein(a) as predictor of atherosclerotic diseases. Results from the prospective Göttingen Risk, Incidence and Prevalence Study (GRIPS)
33. Risk factors in stroke
34. Intermittent claudication: prevalence and risk factors